Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
This intro asks which is better for beginners in 2026: manual or robo investing, covering simplicity, risk, and learning curve for new investors.
25,920 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Solana is under renewed selling pressure as negative funding rates persist and on-chain inflows surge. Analysts warn ...
Capricor's small-cap biotech story hinges on milestones, cash runway, and clinical progress. This guide breaks down w...
Bitcoin remains in a tight range as key U.S. data collide with inflation fears. Traders brace for a volatile weekend ...
Two leading prediction-market platforms are pursuing high-value fundraising as U.S. lawmakers eye tighter rules. Iran...
Ripple unveils a broad expansion in Brazil, layering cross-border payments and digital asset custody for regulated in...
AI momentum is reshaping markets. This guide dives into what best artificial intelligence stocks to buy now, how to s...
A Hong Kong-based stablecoin payments processor plans a $150 million pre-IPO round to fuel a possible U.S. listing th...
A new venue now enables 24/7 crypto trading, including weekends. Early weekend data shows growing interest and liquid...
The Justice Department filed a federal civil rights lawsuit against Harvard, alleging leadership failed to curb antis...
SoFi Technologies edges higher on Monday, breaking a prolonged skid as a key short-seller report lingers in the backg...
Mortgage rates jump 6.5% this spring, reshaping affordability for buyers. As lenders adjust, borrowers weigh higher p...